{"success":true,"data":{"pressRelease":{"id":"74748","rtpr_id":"nGNE4jFx9G","ticker":"IPN","exchange":"Euronext Paris","all_tickers":["IPN"],"title":"REG-Ipsen to acquire Kartos Therapeutics, expanding hemato-oncology late-stage pipeline","author":"Globe Newswire","published_at":"2026-06-29T05:00:00.139Z","article_body":"* Acquisition adds navtemadlin, a late-stage rare blood cancer asset in Phase\nIII. This hemato-oncology program in myelofibrosis expands Ipsen’s growing\nOncology portfolio\n* Navtemadlin, an oral MDM2 inhibitor, has the potential, through disease\nmodifying activity, to transform suboptimal responses to standard of care\nruxolitinib into clinically meaningful responses in patients with\nmyelofibrosis \n* Top-line data from the ongoing Phase III registrational trial POIESIS is\nexpected in 2027\nPARIS, FRANCE AND REDWOOD CITY, U.S., 29 JUNE 2026 - Ipsen (Euronext: IPN;\nADR: IPSEY) and Kartos Therapeutics, announced today they have entered into a\ndefinitive merger agreement under which Ipsen has agreed to acquire Kartos\nTherapeutics. The acquisition adds navtemadlin, an investigational MDM2\ninhibitor designed to restore the natural tumor-suppressing function of p53, a\ncritical tumor-suppressor in myelofibrosis. Data show strong therapeutic\npotential of navtemadlin for intermediate and high-risk TP53 wild-type (wt)\nmyelofibrosis as an add-on treatment for patients with a suboptimal response\nto standard of care ruxolitinib.\n\n“This acquisition further strengthens our late-stage oncology pipeline and\nreflects our continued focus on bringing transformational treatments to people\nliving with cancer,” said David Loew, CEO, Ipsen. “We are excited by the\npotential of navtemadlin to define a new treatment paradigm for patients with\nmyelofibrosis who have a suboptimal response to current standard of care,\naddressing a critical care gap and offering the potential for a new\ntherapeutic option as early as 2028.”\n\nCurrent standard of care ruxolitinib improves splenomegaly and\nmyelofibrosis-related symptoms. However, a significant proportion of patients\nexperience a suboptimal response to ruxolitinib, resulting in treatment\ndiscontinuation. Patient outcomes after ruxolitinib discontinuation are\ndismal, with a median overall survival of approximately 1-2 years. Navtemadlin\nis currently being evaluated in the global Phase III trial POIESIS designed to\nenroll >600 patients across >250 sites, as an add-on therapy to standard of\ncare ruxolitinib in patients with intermediate and high-risk TP53(wt)\nmyelofibrosis who have a suboptimal response to ruxolitinib. The trial builds\non earlier clinical evidence, including a Phase Ib/II trial (KRT-232-109) in\nwhich add-on navtemadlin demonstrated clinically meaningful and\ndisease-modifying activity in myelofibrosis patients who had a suboptimal\nresponse to standard of care ruxolitinib. Data presented at the European\nHematology Association Congress in 2023 showed that at Week 24, in patients\nwith a suboptimal response to ruxolitinib (n=19), 42% achieved at least a 25%\nreduction in spleen volume, 32% achieved at least a 35% reduction in spleen\nvolume, and 32% achieved a total symptom score improvement of at least 50%.\nThese data also showed potential disease modification activity of navtemadlin,\nas evidenced by 71% of evaluable patients (n=7) achieving a ≥20% reduction\nof driver variant allele frequency and 57% showing an improvement in bone\nmarrow fibrosis by Central Review of ≥1 Grade by Week 24.\n\nSrdan Verstovsek, MD, PhD, Chief Medical Officer of Kartos Therapeutics,\ncommented, “As a treating clinician who cared for more than a thousand\npatients with myelofibrosis, I have seen first-hand the significant care gap\nfor patients with myelofibrosis who remain symptomatic or have persistent\nsplenomegaly despite ruxolitinib treatment. Navtemadlin has the potential to\nenhance the existing standard of care through an add-on approach designed to\nmove patients with a suboptimal response into a clinical responder group by\noptimizing their care. We believe this innovative treatment paradigm could\nmeaningfully improve outcomes for patients while avoiding unnecessary\nover-treatment of those already responding well.”\n\n“Myelofibrosis remains a serious and rare blood cancer associated with a\nsubstantial symptom burden and progressive splenomegaly that significantly\nimpact quality of life,” said John Mascarenhas, Professor of Medicine at\nthe Icahn School of Medicine at Mount Sinai and Director of the Center of\nExcellence for Blood Cancers and Myeloid Disorders. “The clinical rationale\nfor combining navtemadlin with ruxolitinib is very compelling, and the\nemerging data suggest the synergistic potential to deepen responses and\naddress the underlying biology of the disease.”\n\n“The Phase III POIESIS trial has the potential to redefine how we treat\npatients with myelofibrosis,\" said Dr Pankit Vachhani, Associate Professor of\nMedicine and Director of Clinical Research Unit at the University of Alabama\nat Birmingham, and Global Principal Investigator of POIESIS. \"It is the\nlargest trial conducted in this disease and uniquely designed to reflect\nreal-world clinical practice. The trial evaluates how adding navtemadlin can\ndeliver more clinically meaningful and durable responses, thereby addressing a\ncritical unmet need. I am excited by the prospect of navtemadlin delivering\ndisease modifying benefits, ushering an era of rational combination therapies\nfor those with suboptimal response to standard therapy, and targeting\ncomplementary disease pathways beyond JAK inhibition alone in\nmyelofibrosis.”\n\nTransaction details\nUnder the terms of the agreement and plan of merger, Ipsen through a\nfully-owned subsidiary, will pay $450 million upfront at closing. Kartos\nTherapeutics shareholders are also eligible to receive additional milestone\npayments of up to $1.3 billion including a significant regulatory approval\nmilestone and sales-based milestones.\n\nThis late-stage transaction is expected to be accretive to Ipsen’s core\noperating income from 2029, with limited dilution to 2026 full-year guidance.\nThe transaction is anticipated to close by the end of Q3 2026, subject to\nfulfilment of customary closing conditions including the expiration of the\nwaiting period under the Hart-Scott-Rodino Antitrust Improvements Act.\n\nAdvisors\nOrrick Herrington & Sutcliffe LLP (DC office) is acting as legal counsel to\nIpsen. Goldman Sachs & Co. LLC and PJT Partners (UK) Ltd are serving as\nfinancial advisors to KARTOS THERAPEUTICS. DLA Piper LLP (NY office) is\nserving as legal counsel to KARTOS THERAPEUTICS.\n\nAbout navtemadlin\nNavtemadlin is an investigational oral MDM2 inhibitor being developed as an\nadd-on therapy to ruxolitinib for patients with myelofibrosis who have a\nsuboptimal response to ruxolitinib. The Phase III POIESIS study is evaluating\nwhether the addition of navtemadlin could improve clinical outcomes compared\nwith ruxolitinib alone in this patient population. Early clinical data\ndemonstrate navtemadlin has the potential to transform suboptimal responses to\nstandard of care ruxolitinib into clinically meaningful responses in patients\nwith intermediate and high risk TP53wt myelofibrosis, to provide both enhanced\nclinical outcomes and potential disease-modifying benefit.\n\nAbout myelofibrosis\nMyelofibrosis is a myeloproliferative neoplasm, frequently linked to\nalterations in the JAK/STAT pathway, in which patients develop bone marrow\nfibrosis due to the abnormal proliferation of hematopoietic stem cells and\nsecretion of fibrogenic cytokines. As marrow function declines, blood\nproduction shifts to other organs, most often the spleen, leading to\nsplenomegaly. Myelofibrosis is characterized by bone marrow failure, fibrosis,\nsplenomegaly and a high symptom burden that can significantly affect quality\nof life, including fatigue, night sweats and other progressive symptoms. It\nalso carries a risk of transformation to acute myeloid leukemia. The median\nage at diagnosis is approximately 67–69 years and the condition affects\naround 1.5 per 100,000 people in the U.S. and Europe. Approximately 75–89%\nof patients are intermediate- or high-risk at diagnosis and more than 95% are\nTP53wt. Ruxolitinib, a JAK inhibitor, is the first-line standard of care;\nhowever, it is estimated that a significant proportion of patients have an\ninitial suboptimal response and approximately 50%-75% discontinue treatment\nafter three years. Median overall survival is typically one to two years after\ntreatment discontinuation, underscoring the need for new strategies that can\nincrease the number of patients that can achieve optimal clinical outcomes.\n\nAbout Ipsen\nWe are a global biopharmaceutical company with a focus on bringing\ntransformative medicines to patients in three therapeutic areas: Oncology,\nRare Disease and Neuroscience. Our pipeline is fueled by internal and external\ninnovation and supported by nearly 100 years of development experience and\nglobal hubs in the U.S., France and the U.K. Our teams in more than 40\ncountries and our partnerships around the world enable us to bring medicines\nto patients in more than 100 countries.\n\nIpsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored\nLevel I American Depositary Receipt program (ADR: IPSEY). For more\ninformation, visit ipsen.com\n(https://www.globenewswire.com/Tracker?data=B-NvuRT-lorlya40ovOERH0bn9uPAgIgbsPfdSHNQDOdWEHj0lAAysswvw3Lg6mBDPSSgVfeCZ3RyxM2zj7CHbOnSFfuyaC594o0VSlLsZsK5-ZMY5JfPxYPQSh2RrGAgUSF5oSdz_o4_Tdd2ewEalqpBC1TdzdzLKroL5NNJdpO5qdRrDfWI8BVX1Y_3DIkMWgNOERq2FJDeKWtZt4Zf1dDN26XegLVOfnxh2fIJjGLpdaeXQX1TFtzaOYjGjgnq8goFlTuFioE-7JtyVxJTVVhOoSc6s4BAUZBzGogcvBUgKHDQbNAH2ttiNA0IJVXAdLzMOgQw_s6E5o7mr32mTYSljUK1OMgGdToJugPvZnLTJjC4Lzrl0l5Qez-ewqQfWn9n_zbzvjn8gtzjezNbA==).\n\nAbout Kartos Therapeutics\nKartos Therapeutics is a clinical-stage biopharmaceutical company developing\nnavtemadlin, a potential best-in-class MDM2 inhibitor. The company is focused\non harnessing the therapeutic potential of p53 pathway activation to develop\ninnovative treatments for patients with myeloproliferative neoplasms,\nincluding myelofibrosis, where substantial unmet medical need persists.\n\n Ipsen Contacts                                                 \n Investors                                                      \n Henry Wheeler   henry.wheeler@ipsen.com     +33 7 66 47 11 49  \n Khalid Deojee   khalid.deojee@ipsen.com     +33 6 66 01 95 26  \n                                                                \n Media                                                          \n Sally Bain      sally.bain@ipsen.com        +1 857 320 0517    \n Anne Liontas    anne.liontas.ext@ipsen.com  +33 7 67 34 72 96  \n                                                                \n                                                                \n\nDisclaimers and/or forward-looking statements\nThe forward-looking statements, objectives and targets contained herein are\nbased on Ipsen’s management strategy, current views and assumptions. Such\nstatements involve known and unknown risks and uncertainties that may cause\nactual results, performance or events to differ materially from those\nanticipated herein. All of the above risks could affect Ipsen’s future\nability to achieve its financial targets, which were set assuming reasonable\nmacroeconomic conditions based on the information available today. Use of the\nwords ‘believes’, ‘anticipates’ and ‘expects’ and similar\nexpressions are intended to identify forward-looking statements, including\nIpsen’s expectations regarding future events, including regulatory filings\nand determinations. Moreover, the targets described in this document were\nprepared without taking into account external-growth assumptions and potential\nfuture acquisitions, which may alter these parameters. These objectives are\nbased on data and assumptions regarded as reasonable by Ipsen. These targets\ndepend on conditions or facts likely to happen in the future, and not\nexclusively on historical data. Actual results may depart significantly from\nthese targets given the occurrence of certain risks and uncertainties, notably\nthe fact that a promising medicine in early development phase or clinical\ntrial may end up never being launched on the market or reaching its commercial\ntargets, notably for regulatory or competition reasons. Ipsen must face or\nmight face competition from generic medicine that might translate into a loss\nof market share. Furthermore, the research and development process involves\nseveral stages each of which involves the substantial risk that Ipsen may fail\nto achieve its objectives and be forced to abandon its efforts with regards to\na medicine in which it has invested significant sums. Therefore, Ipsen cannot\nbe certain that favorable results obtained during preclinical trials will be\nconfirmed subsequently during clinical trials, or that the results of clinical\ntrials will be sufficient to demonstrate the safe and effective nature of the\nmedicine concerned. There can be no guarantees a medicine will receive the\nnecessary regulatory approvals or that the medicine will prove to be\ncommercially successful. If underlying assumptions prove inaccurate or risks\nor uncertainties materialize, actual results may differ materially from those\nset forth in the forward-looking statements. Other risks and uncertainties\ninclude but are not limited to, general industry conditions and competition;\ngeneral economic factors, including interest rate and currency exchange rate\nfluctuations; the impact of pharmaceutical industry regulation and healthcare\nlegislation and risks arising from unexpected regulatory or political changes\nsuch as changes in tax regulation and regulations on trade and tariffs, such\nas protectionist measures, especially in the United States; global trends\ntoward healthcare cost containment; technological advances, new medicine and\npatents attained by competitors; challenges inherent in new-medicine\ndevelopment, including obtaining regulatory approval; Ipsen’s ability to\naccurately predict future market conditions; manufacturing difficulties or\ndelays; financial instability of international economies and sovereign risk;\ndependence on the effectiveness of Ipsen’s patents and other protections for\ninnovative medicines; and the exposure to litigation, including patent\nlitigation, and/or regulatory actions. Ipsen also depends on third parties to\ndevelop and market some of its medicines which could potentially generate\nsubstantial royalties; these partners could behave in such ways which could\ncause damage to Ipsen’s activities and financial results. Ipsen cannot be\ncertain that its partners will fulfil their obligations. It might be unable to\nobtain any benefit from those agreements. A default by any of Ipsen’s\npartners could generate lower revenues than expected. Such situations could\nhave a negative impact on Ipsen’s business, financial position or\nperformance. Ipsen expressly disclaims any obligation or undertaking to update\nor revise any forward-looking statements, targets or estimates contained in\nthis press release to reflect any change in events, conditions, assumptions or\ncircumstances on which any such statements are based, unless so required by\napplicable law. Ipsen’s business is subject to the risk factors outlined in\nits registration documents filed with the French Autorité des Marchés\nFinanciers. The risks and uncertainties set out are not exhaustive and the\nreader is advised to refer to Ipsen’s latest Universal Registration\nDocument, available on ipsen.com\n(https://www.globenewswire.com/Tracker?data=B-NvuRT-lorlya40ovOERPl3VY5QttD0qz3sHuF76ntpudD3y-Ss854fUCfMJCqurttmE9EKWGflGiGqKGN5DIMcjbQsbjUfWA534vhzCD7fEOvBvrertkknmF3AFHt2lma94d_L3JCwpl-xLEahK2706x4uf2iNaExVXWWrOwuWvHVM42Fy6COqgeODQXqN74MorFQmZKWZI4F0viQOoAUerUaWbTBssbrMNevYkmSsm7JNopol8LhSQ6n4-LFai9orLqZCrCcBQEBAplw4WsbNAfFvkIXk8_OzCbJmFTC7yEXrJwr1Hi1FJ599DFHIZzFUcnw9J15UyhGrsmSyvbVlSCJrhY2cgII5SEjK4QLYoGl0kiLvRkVc24OtucgfVaF3s9ChqwuhsrkVC7YLgg==).\n\nAttachment\n*     Ipsen PR_Ipsen to acquire Kartos Therapeutics_29062025\n(https://ml-eu.globenewswire.com/Resource/Download/c40d4372-ce56-4db4-a361-0a91a6af2c1c)","article_body_html":"","raw_payload":{"data":{"id":"nGNE4jFx9G","title":"REG-Ipsen to acquire Kartos Therapeutics, expanding hemato-oncology late-stage pipeline","author":"Globe Newswire","ticker":"IPN","created":"2026-06-29T05:00:00.139Z","tickers":["IPN"],"exchange":"Euronext Paris","article_body":"* Acquisition adds navtemadlin, a late-stage rare blood cancer asset in Phase\nIII. This hemato-oncology program in myelofibrosis expands Ipsen’s growing\nOncology portfolio\n* Navtemadlin, an oral MDM2 inhibitor, has the potential, through disease\nmodifying activity, to transform suboptimal responses to standard of care\nruxolitinib into clinically meaningful responses in patients with\nmyelofibrosis \n* Top-line data from the ongoing Phase III registrational trial POIESIS is\nexpected in 2027\nPARIS, FRANCE AND REDWOOD CITY, U.S., 29 JUNE 2026 - Ipsen (Euronext: IPN;\nADR: IPSEY) and Kartos Therapeutics, announced today they have entered into a\ndefinitive merger agreement under which Ipsen has agreed to acquire Kartos\nTherapeutics. The acquisition adds navtemadlin, an investigational MDM2\ninhibitor designed to restore the natural tumor-suppressing function of p53, a\ncritical tumor-suppressor in myelofibrosis. Data show strong therapeutic\npotential of navtemadlin for intermediate and high-risk TP53 wild-type (wt)\nmyelofibrosis as an add-on treatment for patients with a suboptimal response\nto standard of care ruxolitinib.\n\n“This acquisition further strengthens our late-stage oncology pipeline and\nreflects our continued focus on bringing transformational treatments to people\nliving with cancer,” said David Loew, CEO, Ipsen. “We are excited by the\npotential of navtemadlin to define a new treatment paradigm for patients with\nmyelofibrosis who have a suboptimal response to current standard of care,\naddressing a critical care gap and offering the potential for a new\ntherapeutic option as early as 2028.”\n\nCurrent standard of care ruxolitinib improves splenomegaly and\nmyelofibrosis-related symptoms. However, a significant proportion of patients\nexperience a suboptimal response to ruxolitinib, resulting in treatment\ndiscontinuation. Patient outcomes after ruxolitinib discontinuation are\ndismal, with a median overall survival of approximately 1-2 years. Navtemadlin\nis currently being evaluated in the global Phase III trial POIESIS designed to\nenroll >600 patients across >250 sites, as an add-on therapy to standard of\ncare ruxolitinib in patients with intermediate and high-risk TP53(wt)\nmyelofibrosis who have a suboptimal response to ruxolitinib. The trial builds\non earlier clinical evidence, including a Phase Ib/II trial (KRT-232-109) in\nwhich add-on navtemadlin demonstrated clinically meaningful and\ndisease-modifying activity in myelofibrosis patients who had a suboptimal\nresponse to standard of care ruxolitinib. Data presented at the European\nHematology Association Congress in 2023 showed that at Week 24, in patients\nwith a suboptimal response to ruxolitinib (n=19), 42% achieved at least a 25%\nreduction in spleen volume, 32% achieved at least a 35% reduction in spleen\nvolume, and 32% achieved a total symptom score improvement of at least 50%.\nThese data also showed potential disease modification activity of navtemadlin,\nas evidenced by 71% of evaluable patients (n=7) achieving a ≥20% reduction\nof driver variant allele frequency and 57% showing an improvement in bone\nmarrow fibrosis by Central Review of ≥1 Grade by Week 24.\n\nSrdan Verstovsek, MD, PhD, Chief Medical Officer of Kartos Therapeutics,\ncommented, “As a treating clinician who cared for more than a thousand\npatients with myelofibrosis, I have seen first-hand the significant care gap\nfor patients with myelofibrosis who remain symptomatic or have persistent\nsplenomegaly despite ruxolitinib treatment. Navtemadlin has the potential to\nenhance the existing standard of care through an add-on approach designed to\nmove patients with a suboptimal response into a clinical responder group by\noptimizing their care. We believe this innovative treatment paradigm could\nmeaningfully improve outcomes for patients while avoiding unnecessary\nover-treatment of those already responding well.”\n\n“Myelofibrosis remains a serious and rare blood cancer associated with a\nsubstantial symptom burden and progressive splenomegaly that significantly\nimpact quality of life,” said John Mascarenhas, Professor of Medicine at\nthe Icahn School of Medicine at Mount Sinai and Director of the Center of\nExcellence for Blood Cancers and Myeloid Disorders. “The clinical rationale\nfor combining navtemadlin with ruxolitinib is very compelling, and the\nemerging data suggest the synergistic potential to deepen responses and\naddress the underlying biology of the disease.”\n\n“The Phase III POIESIS trial has the potential to redefine how we treat\npatients with myelofibrosis,\" said Dr Pankit Vachhani, Associate Professor of\nMedicine and Director of Clinical Research Unit at the University of Alabama\nat Birmingham, and Global Principal Investigator of POIESIS. \"It is the\nlargest trial conducted in this disease and uniquely designed to reflect\nreal-world clinical practice. The trial evaluates how adding navtemadlin can\ndeliver more clinically meaningful and durable responses, thereby addressing a\ncritical unmet need. I am excited by the prospect of navtemadlin delivering\ndisease modifying benefits, ushering an era of rational combination therapies\nfor those with suboptimal response to standard therapy, and targeting\ncomplementary disease pathways beyond JAK inhibition alone in\nmyelofibrosis.”\n\nTransaction details\nUnder the terms of the agreement and plan of merger, Ipsen through a\nfully-owned subsidiary, will pay $450 million upfront at closing. Kartos\nTherapeutics shareholders are also eligible to receive additional milestone\npayments of up to $1.3 billion including a significant regulatory approval\nmilestone and sales-based milestones.\n\nThis late-stage transaction is expected to be accretive to Ipsen’s core\noperating income from 2029, with limited dilution to 2026 full-year guidance.\nThe transaction is anticipated to close by the end of Q3 2026, subject to\nfulfilment of customary closing conditions including the expiration of the\nwaiting period under the Hart-Scott-Rodino Antitrust Improvements Act.\n\nAdvisors\nOrrick Herrington & Sutcliffe LLP (DC office) is acting as legal counsel to\nIpsen. Goldman Sachs & Co. LLC and PJT Partners (UK) Ltd are serving as\nfinancial advisors to KARTOS THERAPEUTICS. DLA Piper LLP (NY office) is\nserving as legal counsel to KARTOS THERAPEUTICS.\n\nAbout navtemadlin\nNavtemadlin is an investigational oral MDM2 inhibitor being developed as an\nadd-on therapy to ruxolitinib for patients with myelofibrosis who have a\nsuboptimal response to ruxolitinib. The Phase III POIESIS study is evaluating\nwhether the addition of navtemadlin could improve clinical outcomes compared\nwith ruxolitinib alone in this patient population. Early clinical data\ndemonstrate navtemadlin has the potential to transform suboptimal responses to\nstandard of care ruxolitinib into clinically meaningful responses in patients\nwith intermediate and high risk TP53wt myelofibrosis, to provide both enhanced\nclinical outcomes and potential disease-modifying benefit.\n\nAbout myelofibrosis\nMyelofibrosis is a myeloproliferative neoplasm, frequently linked to\nalterations in the JAK/STAT pathway, in which patients develop bone marrow\nfibrosis due to the abnormal proliferation of hematopoietic stem cells and\nsecretion of fibrogenic cytokines. As marrow function declines, blood\nproduction shifts to other organs, most often the spleen, leading to\nsplenomegaly. Myelofibrosis is characterized by bone marrow failure, fibrosis,\nsplenomegaly and a high symptom burden that can significantly affect quality\nof life, including fatigue, night sweats and other progressive symptoms. It\nalso carries a risk of transformation to acute myeloid leukemia. The median\nage at diagnosis is approximately 67–69 years and the condition affects\naround 1.5 per 100,000 people in the U.S. and Europe. Approximately 75–89%\nof patients are intermediate- or high-risk at diagnosis and more than 95% are\nTP53wt. Ruxolitinib, a JAK inhibitor, is the first-line standard of care;\nhowever, it is estimated that a significant proportion of patients have an\ninitial suboptimal response and approximately 50%-75% discontinue treatment\nafter three years. Median overall survival is typically one to two years after\ntreatment discontinuation, underscoring the need for new strategies that can\nincrease the number of patients that can achieve optimal clinical outcomes.\n\nAbout Ipsen\nWe are a global biopharmaceutical company with a focus on bringing\ntransformative medicines to patients in three therapeutic areas: Oncology,\nRare Disease and Neuroscience. Our pipeline is fueled by internal and external\ninnovation and supported by nearly 100 years of development experience and\nglobal hubs in the U.S., France and the U.K. Our teams in more than 40\ncountries and our partnerships around the world enable us to bring medicines\nto patients in more than 100 countries.\n\nIpsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored\nLevel I American Depositary Receipt program (ADR: IPSEY). For more\ninformation, visit ipsen.com\n(https://www.globenewswire.com/Tracker?data=B-NvuRT-lorlya40ovOERH0bn9uPAgIgbsPfdSHNQDOdWEHj0lAAysswvw3Lg6mBDPSSgVfeCZ3RyxM2zj7CHbOnSFfuyaC594o0VSlLsZsK5-ZMY5JfPxYPQSh2RrGAgUSF5oSdz_o4_Tdd2ewEalqpBC1TdzdzLKroL5NNJdpO5qdRrDfWI8BVX1Y_3DIkMWgNOERq2FJDeKWtZt4Zf1dDN26XegLVOfnxh2fIJjGLpdaeXQX1TFtzaOYjGjgnq8goFlTuFioE-7JtyVxJTVVhOoSc6s4BAUZBzGogcvBUgKHDQbNAH2ttiNA0IJVXAdLzMOgQw_s6E5o7mr32mTYSljUK1OMgGdToJugPvZnLTJjC4Lzrl0l5Qez-ewqQfWn9n_zbzvjn8gtzjezNbA==).\n\nAbout Kartos Therapeutics\nKartos Therapeutics is a clinical-stage biopharmaceutical company developing\nnavtemadlin, a potential best-in-class MDM2 inhibitor. The company is focused\non harnessing the therapeutic potential of p53 pathway activation to develop\ninnovative treatments for patients with myeloproliferative neoplasms,\nincluding myelofibrosis, where substantial unmet medical need persists.\n\n Ipsen Contacts                                                 \n Investors                                                      \n Henry Wheeler   henry.wheeler@ipsen.com     +33 7 66 47 11 49  \n Khalid Deojee   khalid.deojee@ipsen.com     +33 6 66 01 95 26  \n                                                                \n Media                                                          \n Sally Bain      sally.bain@ipsen.com        +1 857 320 0517    \n Anne Liontas    anne.liontas.ext@ipsen.com  +33 7 67 34 72 96  \n                                                                \n                                                                \n\nDisclaimers and/or forward-looking statements\nThe forward-looking statements, objectives and targets contained herein are\nbased on Ipsen’s management strategy, current views and assumptions. Such\nstatements involve known and unknown risks and uncertainties that may cause\nactual results, performance or events to differ materially from those\nanticipated herein. All of the above risks could affect Ipsen’s future\nability to achieve its financial targets, which were set assuming reasonable\nmacroeconomic conditions based on the information available today. Use of the\nwords ‘believes’, ‘anticipates’ and ‘expects’ and similar\nexpressions are intended to identify forward-looking statements, including\nIpsen’s expectations regarding future events, including regulatory filings\nand determinations. Moreover, the targets described in this document were\nprepared without taking into account external-growth assumptions and potential\nfuture acquisitions, which may alter these parameters. These objectives are\nbased on data and assumptions regarded as reasonable by Ipsen. These targets\ndepend on conditions or facts likely to happen in the future, and not\nexclusively on historical data. Actual results may depart significantly from\nthese targets given the occurrence of certain risks and uncertainties, notably\nthe fact that a promising medicine in early development phase or clinical\ntrial may end up never being launched on the market or reaching its commercial\ntargets, notably for regulatory or competition reasons. Ipsen must face or\nmight face competition from generic medicine that might translate into a loss\nof market share. Furthermore, the research and development process involves\nseveral stages each of which involves the substantial risk that Ipsen may fail\nto achieve its objectives and be forced to abandon its efforts with regards to\na medicine in which it has invested significant sums. Therefore, Ipsen cannot\nbe certain that favorable results obtained during preclinical trials will be\nconfirmed subsequently during clinical trials, or that the results of clinical\ntrials will be sufficient to demonstrate the safe and effective nature of the\nmedicine concerned. There can be no guarantees a medicine will receive the\nnecessary regulatory approvals or that the medicine will prove to be\ncommercially successful. If underlying assumptions prove inaccurate or risks\nor uncertainties materialize, actual results may differ materially from those\nset forth in the forward-looking statements. Other risks and uncertainties\ninclude but are not limited to, general industry conditions and competition;\ngeneral economic factors, including interest rate and currency exchange rate\nfluctuations; the impact of pharmaceutical industry regulation and healthcare\nlegislation and risks arising from unexpected regulatory or political changes\nsuch as changes in tax regulation and regulations on trade and tariffs, such\nas protectionist measures, especially in the United States; global trends\ntoward healthcare cost containment; technological advances, new medicine and\npatents attained by competitors; challenges inherent in new-medicine\ndevelopment, including obtaining regulatory approval; Ipsen’s ability to\naccurately predict future market conditions; manufacturing difficulties or\ndelays; financial instability of international economies and sovereign risk;\ndependence on the effectiveness of Ipsen’s patents and other protections for\ninnovative medicines; and the exposure to litigation, including patent\nlitigation, and/or regulatory actions. Ipsen also depends on third parties to\ndevelop and market some of its medicines which could potentially generate\nsubstantial royalties; these partners could behave in such ways which could\ncause damage to Ipsen’s activities and financial results. Ipsen cannot be\ncertain that its partners will fulfil their obligations. It might be unable to\nobtain any benefit from those agreements. A default by any of Ipsen’s\npartners could generate lower revenues than expected. Such situations could\nhave a negative impact on Ipsen’s business, financial position or\nperformance. Ipsen expressly disclaims any obligation or undertaking to update\nor revise any forward-looking statements, targets or estimates contained in\nthis press release to reflect any change in events, conditions, assumptions or\ncircumstances on which any such statements are based, unless so required by\napplicable law. Ipsen’s business is subject to the risk factors outlined in\nits registration documents filed with the French Autorité des Marchés\nFinanciers. The risks and uncertainties set out are not exhaustive and the\nreader is advised to refer to Ipsen’s latest Universal Registration\nDocument, available on ipsen.com\n(https://www.globenewswire.com/Tracker?data=B-NvuRT-lorlya40ovOERPl3VY5QttD0qz3sHuF76ntpudD3y-Ss854fUCfMJCqurttmE9EKWGflGiGqKGN5DIMcjbQsbjUfWA534vhzCD7fEOvBvrertkknmF3AFHt2lma94d_L3JCwpl-xLEahK2706x4uf2iNaExVXWWrOwuWvHVM42Fy6COqgeODQXqN74MorFQmZKWZI4F0viQOoAUerUaWbTBssbrMNevYkmSsm7JNopol8LhSQ6n4-LFai9orLqZCrCcBQEBAplw4WsbNAfFvkIXk8_OzCbJmFTC7yEXrJwr1Hi1FJ599DFHIZzFUcnw9J15UyhGrsmSyvbVlSCJrhY2cgII5SEjK4QLYoGl0kiLvRkVc24OtucgfVaF3s9ChqwuhsrkVC7YLgg==).\n\nAttachment\n*     Ipsen PR_Ipsen to acquire Kartos Therapeutics_29062025\n(https://ml-eu.globenewswire.com/Resource/Download/c40d4372-ce56-4db4-a361-0a91a6af2c1c)"},"type":"article","timestamp":"2026-06-29T05:00:00.25376796Z","server_sent_at_ms":1782709200253},"received_at":"2026-06-29T05:00:00.421Z","source_url":null},"analysis":{"id":"64108","press_release_id":"74748","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"m_and_a","narrative":"Ipsen has entered into a definitive merger agreement to acquire Kartos Therapeutics, adding the late-stage MDM2 inhibitor navtemadlin to its oncology pipeline.\n\nThe deal includes a $450 million upfront payment and up to $1.3 billion in milestone payments, with top-line Phase III data from the POIESIS trial expected in 2027.\n\nManagement expects the transaction to be accretive to core operating income from 2029, with limited dilution to 2026 full-year guidance, and anticipates closing by the end of Q3 2026.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Ipsen expands oncology footprint with $1.75B Kartos acquisition, targeting myelofibrosis market with late-stage navtemadlin."},"keyFigures":{"customDimensions":{"upfront_payment":450000000,"milestone_payments":1300000000}},"quotedText":"This acquisition further strengthens our late-stage oncology pipeline and reflects our continued focus on bringing transformational treatments to people living with cancer","namedEntities":{"people":[{"name":"David Loew","role":"CEO, Ipsen"},{"name":"Srdan Verstovsek","role":"Chief Medical Officer, Kartos Therapeutics"},{"name":"John Mascarenhas","role":"Professor of Medicine, Icahn School of Medicine at Mount Sinai"},{"name":"Pankit Vachhani","role":"Global Principal Investigator of POIESIS"},{"name":"Henry Wheeler","role":"Investor Relations, Ipsen"},{"name":"Khalid Deojee","role":"Investor Relations, Ipsen"},{"name":"Sally Bain","role":"Media, Ipsen"},{"name":"Anne Liontas","role":"Media, Ipsen"}],"products":["navtemadlin","ruxolitinib"],"companies":[{"name":"Ipsen","ticker":"IPN","relationship":"acquirer"},{"name":"Kartos Therapeutics","relationship":"target"},{"name":"Orrick Herrington & Sutcliffe LLP","relationship":"legal counsel to Ipsen"},{"name":"Goldman Sachs & Co. LLC","relationship":"financial advisor to Kartos"},{"name":"PJT Partners (UK) Ltd","relationship":"financial advisor to Kartos"},{"name":"DLA Piper LLP","relationship":"legal counsel to Kartos"}],"dollarAmounts":[{"amount":"$450 million","context":"upfront payment at closing"},{"amount":"$1.3 billion","context":"additional milestone payments"}]},"materialImpact":{"score":5,"reasoning":"Definitive merger agreement to acquire a late-stage oncology asset (navtemadlin) with Phase III data expected in 2027. The deal adds a potential best-in-class therapy for myelofibrosis, expanding Ipsen's oncology portfolio with limited near-term dilution and expected accretion from 2029."},"tickerRelevance":{"others":[],"primary":"IPN"},"globalImportance":65,"audienceRelevance":45,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap","eventGravity":"m_and_a","sectorWeight":"high","householdBrandBoost":"low","marketCapAdjustment":"neutral","retailFavoriteBoost":"none"}},"event_type":"m_and_a","event_type_secondary":null,"sentiment":"bullish","material_impact_score":5,"narrative":"Ipsen has entered into a definitive merger agreement to acquire Kartos Therapeutics, adding the late-stage MDM2 inhibitor navtemadlin to its oncology pipeline.\n\nThe deal includes a $450 million upfront payment and up to $1.3 billion in milestone payments, with top-line Phase III data from the POIESIS trial expected in 2027.\n\nManagement expects the transaction to be accretive to core operating income from 2029, with limited dilution to 2026 full-year guidance, and anticipates closing by the end of Q3 2026.","key_figures":{"customDimensions":{"upfront_payment":450000000,"milestone_payments":1300000000}},"named_entities":{"people":[{"name":"David Loew","role":"CEO, Ipsen"},{"name":"Srdan Verstovsek","role":"Chief Medical Officer, Kartos Therapeutics"},{"name":"John Mascarenhas","role":"Professor of Medicine, Icahn School of Medicine at Mount Sinai"},{"name":"Pankit Vachhani","role":"Global Principal Investigator of POIESIS"},{"name":"Henry Wheeler","role":"Investor Relations, Ipsen"},{"name":"Khalid Deojee","role":"Investor Relations, Ipsen"},{"name":"Sally Bain","role":"Media, Ipsen"},{"name":"Anne Liontas","role":"Media, Ipsen"}],"products":["navtemadlin","ruxolitinib"],"companies":[{"name":"Ipsen","ticker":"IPN","relationship":"acquirer"},{"name":"Kartos Therapeutics","relationship":"target"},{"name":"Orrick Herrington & Sutcliffe LLP","relationship":"legal counsel to Ipsen"},{"name":"Goldman Sachs & Co. LLC","relationship":"financial advisor to Kartos"},{"name":"PJT Partners (UK) Ltd","relationship":"financial advisor to Kartos"},{"name":"DLA Piper LLP","relationship":"legal counsel to Kartos"}],"dollarAmounts":[{"amount":"$450 million","context":"upfront payment at closing"},{"amount":"$1.3 billion","context":"additional milestone payments"}]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-29T05:00:26.100Z","global_importance":65,"audience_relevance":45,"importance_components":{"tickerTier":"mid-cap","eventGravity":"m_and_a","sectorWeight":"high","householdBrandBoost":"low","marketCapAdjustment":"neutral","retailFavoriteBoost":"none"}},"durationMs":25659,"modelName":"george-droid-qwen-72b"}}